Gomekli is the second ever FDA-approved treatment for rare tumor disease, NF1-PN and the first to be approved for both adult and pediatric patients.
Neurofibromatosis type 1 (NF1) is the most common of the three types of neurofibromatosis and is also one of the most common inherited neurological disorders, affecting about 1 in 3,000 people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback